May #23 : Devil's in the Data - by Walter Armstrong and Ronnilyn Pustil

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Plastic Explosion

Who's Afraid of Reinfection?

Don't Call Him 'Poster Boy'

Saving Faces

Grandmother Theresa

Surgical Rotations

Fate Expectations

Mirror Image


Mailbox-May 1997

On Native Ground

Move Over, Elmo

Devil's in the Data

Cheesehead Shalala

Don't Cry for Me, Marijuana

The Pot Thickens

Fellatio Felon

Diver Dissed

French Roast

AZT Linked to Cancer in Mice

The Philadelphia Story

Fashion Victims

Say What

Legacy-Tom Stoddard

Skin Deep


She's Going to Live!


A Delicate Bully Pulpit

La Dolce Morte

Damned but Beautiful

Dressed for Arrest

POZ Picks-May 1997

Hymn to a Gym

Bodies of Work

Healing Beauty

Longtime Companion

For Doom, the Bell Tolls

Whatta Cut Up

Health Club Horrors


Protein Power

The Missing Zinc

Bad Blood

Lovely Labs

The Biology of Beauty

It's My Party


Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

May 1997

Devil's in the Data

by Walter Armstrong and Ronnilyn Pustil

Embarassment of riches at drug confab

There was high drama this winter at the once-dull Conference on Retroviruses and Opportunistic Infections. Primed by protease promises, 2,500 researchers, activists, drug execs and journalists crammed into the Washington, DC meeting. But an equal number were shut out because of caps on attendance, and about 100 pissed-off PWAs and a snarling star scientist or two were turned away at the gate. Inside, other star scientists were spotted with burly bodyguards, and bomb threats were reported. Researchers spoke of first-ever plunges in hospitalization and death rates of PWAs in many cities. Welcome to the Age of Protease.

The confab was long on scientific data but short on practical application. Heads spun at the stats from studies comparing antiviral-drug combinations, but questions of drug management--when to start, say, or with which combo--hung in the air. In a prickly presentation, Dutch researcher Dr. Joep Lange cut to the chase: Lambasting bureaucratic regulations, drug-company greed and researcher stupidity, he demanded studies that test the best drug options rather than those favored by manufacturers. Next up? "The meeting made it clear we need to evaluate whether d4T should replace AZT as the standard treatment," said activist Richard Jefferys.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.